HS LifeSciences

Founder and Managing Partner Dr. Gunnar Weikert and Managing Partner Dr. Kristian Rettig share final investment authority, per the firm's official communications. Both are physicians by training. They are supported by a scientific advisory board of external clinicians who participate in due diligence.

The firm makes equity investments in early-stage and growth-stage life-science companies, primarily in the DACH region and select other European markets. It focuses on biotech, medtech, diagnostics, and digital health. The firm takes an active, board-level role and typically leads or co-leads rounds.

The firm leans heavily on its network of practicing physicians, academic medical centers, and European research institutions for proprietary deal flow. Its managing partners' clinical backgrounds and the firm's scientific advisory board give it early visibility into science emerging from university labs and teaching hospitals.

HS LifeSciences co-invests with specialist healthcare investors and generalist venture firms. It seeks to attract co-investors who can add clinical or regulatory expertise, not just capital. The firm has syndicated rounds with international life-science VCs and corporate venture arms.

It is an institutional fund manager, not a single-family office. The firm raises capital from limited partners, which typically include European institutional investors, family offices, and development banks, based on public fund filings.